Tumor Microenvironment-Responsive Nanomedicine: Targeting Hypoxia, Acidity, and ECM for Smart Drug Release

The tumor microenvironment (TME) plays a pivotal role in cancer progression, therapeutic resistance, and metastasis. Characterized by hypoxia, acidic pH, and a dense extracellular matrix (ECM), the TME creates a unique niche that conventional therapies struggle to penetrate. Nanomedicine has emerged as a promising platform to overcome these barriers by designing smart, stimuli-responsive drug delivery systems that selectively respond to TME-specific cues. This review provides a comprehensive overview of tumor microenvironment-responsive nanomedicines, with a focus on their ability to exploit hypoxia, acidity, and ECM abnormalities for targeted and controlled drug release. We explore the design principles, recent advances, and therapeutic benefits of such systems, highlighting their role in enhancing drug bioavailability, minimizing off-target toxicity, and improving clinical outcomes. Furthermore, we discuss translational challenges and future directions to realize the full potential of these nanocarriers in personalized cancer therapy. Keywords: Tumor microenvironment; Hypoxia-responsive nanomedicine; pH-sensitive drug delivery; ECM-targeted nanoparticles; Smart drug release systems